Glenmark Pharmaceuticals has executed business purchase agreement for transfer of the company’s API business to its wholly owned subsidiary — Glenmark Life Sciences on October 9, 2018. The transaction is expected to be completed in the next 2-3 months.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).